Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
December 5, 2018
Transgene Announces Upcoming Investor Meetings
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (TNG.PA) today announces that Management will participate in the upcoming investor events set out below. Transgene will meet institutional investors at ...
December 4, 2018
RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
December 4, 2018
Celyad Presents Update on CYAD-01 Hematological Malignancies Clinical Program at 60th ASH Annual Meeting
MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
December 4, 2018
ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of ...
December 4, 2018
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based ...
December 4, 2018
Eiger BioPharmaceuticals to Host R&D Day in New York City
PALO ALTO, Calif., Dec. 4, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, ...
December 4, 2018
Novus Therapeutics Announces Formation of Scientific Advisory Board
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), ...
December 4, 2018
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
December 4, 2018
Theravance Biopharma to Highlight Innovative Early Research and Clinical Development at R&D Day on December 12 in New York
DUBLIN, Dec. 4, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ...
December 4, 2018
Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting
WATERTOWN, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and ...
December 4, 2018
Inspire Medical Systems, Inc. Announces Proposed Offering of Common Stock
MINNEAPOLIS, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:  INSP) (“Inspire”), a medical technology company focused on the development and commercialization of ...
December 4, 2018
VALNEVA to Conduct Investor and Partnering Meetings During the 37th Annual J.P. Morgan Healthcare Conference
Saint-Herblain (France), December 4, 2018 - Valneva SE ("Valneva"), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today ...
December 3, 2018
Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
BOSTON, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today ...
December 3, 2018
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
PALO ALTO, Calif., Dec. 3, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare ...
December 3, 2018
INNATE PHARMA : Updated results that support advancement of IPH4102 in refractory Sézary syndrome at ASH 2018
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH), today announced updated data from the Phase I trial (including an expansion cohort) evaluating ...
December 3, 2018
miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
December 3, 2018
ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting
ArQule, Inc. (ARQL) yesterday presented preliminary results from the Company’s Phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible inhibitor ...
December 3, 2018
Sierra Oncology Reports Robust Transfusion Independence Rates in Transfusion Dependent Myelofibrosis Patients Treated with Momelotinib
VANCOUVER , Dec. 3, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of ...
December 3, 2018
RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 03, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
December 3, 2018
Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
SAN DIEGO and TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) today announced the presentation of preclinical data from ...
Page 23 of 138